New incident report
Incident Report Number: 2009-2724
Registrant Reference Number: Prosar 1-18984658
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: UNITED STATES
Prov / State: TENNESSEE
PMRA Registration No. PMRA Submission No. EPA Registration No.
Product Name: Phenothrin-based non-specific Ultraguard Flea/Tick Drops for Dogs
Liquid
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Unknown
Medical Professional
Dog / Chien
Pomeranian
1
Male
5
9.7
lbs
Skin
Unknown / Inconnu
Unknown / Inconnu
System
Persisted until death
Yes
Unknown
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
1-18984658: A reporter (veterinarian) called on 06/29/2009 to report the exposure of a dog to a flea and tick product containing the active ingredient Phenothrin. According to the reporter, the product was applied to the dog on 06/28/2009. An unknown time following product application, the dog developed lethargy and had a seizure. The owner called the veterinarian who recommended bathing the dog and having it evaluated the following day. The morning of the report, the dog was weak and the owner bathed the dog to remove the product. On presentation to the reporter, the dog was weak, had pale mucous membranes, was dehydrated, hypothermic, having brief seizures, coughing and fainting. A complete blood count revealed a slightly elevated white blood cell count. Blood could not be obtained for a chemistry profile. The dog had been treated with dextrose, dexamethasone S.P., IV fluids, and was being warmed. X-rays of the chest were within normal limits. The dog's heartworm status was unknown. The reporter was advised that pyrethroid toxicity can manifest as seizures/tremors, but the other signs described are not consistent with product exposure. A recommendation was made to consider shock, heartworm disease, or other toxins as a cause for the signs. The methocarbamol dose was provided and the reporter was encouraged to continue symptomatic and supportive care while ruling out other causes for the signs. On follow up, the reporter stated that the dog developed pulmonary edema and died. The reporter was provided the company's necropsy program information. No further information was obtained.
Death